Page last updated: 2024-12-09

1-ethyl-3-(4-methylphenyl)sulfonylthiourea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-ethyl-3-(4-methylphenyl)sulfonylthiourea, often abbreviated as **EMST**, is a **small molecule** that has garnered significant attention in research due to its unique pharmacological properties.

**Chemical Structure and Properties:**

* EMST is a synthetic compound with a thiourea core, an ethyl group at the N1 position, and a 4-methylphenyl sulfonyl group at the N3 position.
* It is a white, crystalline solid with a molecular weight of 286.36 g/mol.
* EMST is soluble in organic solvents like ethanol and dimethyl sulfoxide (DMSO).

**Pharmacological Importance:**

EMST has been investigated for its potential in various research areas, including:

* **Anti-inflammatory Activity:** Studies have shown that EMST exhibits anti-inflammatory effects by inhibiting the production of inflammatory mediators like nitric oxide (NO) and prostaglandins. This activity is linked to its ability to suppress the activation of nuclear factor kappa-B (NF-κB), a key transcription factor involved in inflammation.
* **Antioxidant Properties:** EMST acts as an antioxidant by scavenging free radicals and protecting cells from oxidative damage.
* **Anticancer Activity:** Research suggests that EMST possesses anticancer properties. It has been shown to induce apoptosis (programmed cell death) in cancer cells and inhibit their growth and proliferation. This activity might be associated with its ability to interfere with signaling pathways involved in cell cycle regulation and angiogenesis (formation of new blood vessels).
* **Neuroprotective Effects:** EMST has been explored for its potential to protect neurons against damage caused by various insults, such as stroke, neurodegenerative diseases, and traumatic brain injury. It has been shown to reduce neuronal cell death and improve neurological function in animal models.
* **Modulation of Ion Channels:** EMST can interact with and modulate the activity of ion channels, particularly those involved in neuronal excitability and synaptic transmission. This interaction may contribute to its neuroprotective and anti-inflammatory effects.

**Research Applications:**

* **Drug Development:** EMST is being investigated as a potential drug candidate for treating inflammatory diseases, cancer, neurodegenerative disorders, and other conditions.
* **Preclinical Studies:** EMST is used in animal models to study the mechanisms underlying its pharmacological actions and to evaluate its therapeutic potential.
* **Target Identification:** Research utilizing EMST aims to identify the specific molecular targets responsible for its biological effects. This information can be valuable for developing more targeted therapies.

**Note:** It is important to note that EMST is still under investigation, and further research is required to fully understand its efficacy and safety in humans. Clinical trials are needed to assess its potential as a therapeutic agent.

Cross-References

ID SourceID
PubMed CID914066
CHEMBL ID1441276
CHEBI ID109684

Synonyms (15)

Synonym
UPCMLD0ENAT5307404:001
MLS000580097 ,
smr000199627
n-[(ethylamino)carbonothioyl]-4-methylbenzenesulfonamide
n-(ethylcarbamothioyl)-4-methylbenzenesulfonamide
STK244638
CHEBI:109684
AKOS001081047
1-ethyl-3-(4-methylphenyl)sulfonylthiourea
HMS2541K03
CHEMBL1441276
Q27188857
sr-01000274143
SR-01000274143-1
Z57049055
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency3.53970.140911.194039.8107AID2451
thioredoxin reductaseRattus norvegicus (Norway rat)Potency15.84890.100020.879379.4328AID588453
phosphopantetheinyl transferaseBacillus subtilisPotency17.78280.141337.9142100.0000AID1490
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency2.23870.28189.721235.4813AID2326
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency31.62280.035520.977089.1251AID504332
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency24.80330.00798.23321,122.0200AID2546; AID2551
DNA dC->dU-editing enzyme APOBEC-3F isoform aHomo sapiens (human)Potency14.12540.025911.239831.6228AID602313
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
polyadenylate-binding protein 1Homo sapiens (human)IC50 (µMol)66.00004.910023.702976.1900AID602259; AID602260
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]